Noninvasix:

Brain hypoxia, characterized by restricted blood flow to the brain, counts for 23% of all neonatal deaths worldwide making the development of an accurate and precise patient monitoring system a top maternal-fetal health priority. Noninvasix's novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation to accurately measure the amount of oxygen a baby is receiving in real time. Using Noninvasix’s technology, the typical 12-bed NICU would save $1.1 million per year due to complications and 3rd party payers would save $2.4 million to $6.2 million by reducing the lifelong direct medical costs for children with hypoxia-induced cerebral palsy.